BiotechTube

quetiapine + olanzapine + risperidone

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psychotic Disorders

Conditions

Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders

Trial Timeline

Aug 1, 2002 → Aug 1, 2006

NCT ID
NCT00222495

About quetiapine + olanzapine + risperidone

quetiapine + olanzapine + risperidone is a pre-clinical stage product being developed by AstraZeneca for Psychotic Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00222495. Target conditions include Psychotic Disorders, Schizophrenia, Schizophreniform Disorders.

What happened to similar drugs?

2 of 7 similar drugs in Psychotic Disorders were approved

Approved (2) Terminated (4) Active (2)
❌quetiapineAstraZenecaPhase 3
🔄QuetiapineAstraZenecaPhase 3
❌QuetiapineAstraZenecaPhase 3
✅Asenapine 5-20 mg daily + Placebo 1-4 tablets dailyMerckApproved
✅Ziprasidone HCL (oral)PfizerApproved
🔄AripiprazoleBristol Myers SquibbPhase 3
❌mifepristone + placeboCorcept TherapeuticsPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00222495Pre-clinicalCompleted

Competing Products

14 competing products in Psychotic Disorders

See all competitors
ProductCompanyStageHype Score
Olanzapine, Amantadine + Olanzapine and placeboEli LillyPhase 1
29
risperidone IR and LAI formulationJohnson & JohnsonPhase 1
29
quetiapineAstraZenecaPhase 3
32
QuetiapineAstraZenecaPhase 3
40
QuetiapineAstraZenecaPhase 3
32
Asenapine 5-20 mg daily + Placebo 1-4 tablets dailyMerckApproved
43
Ziprasidone HCL (oral)PfizerApproved
35
AripiprazoleBristol Myers SquibbPhase 3
40
Aripiprazole + Risperidone/QuetiapineBristol Myers SquibbPre-clinical
26
mifepristone + placeboCorcept TherapeuticsPhase 3
29
Miricorlilant + Miricorlilant + PlaceboCorcept TherapeuticsPhase 2
32
Miricorilant + FluvoxamineCorcept TherapeuticsPhase 1
26
Miricorilant + PlaceboCorcept TherapeuticsPhase 2
32
Olanzapine + CORT118335 + PlaceboCorcept TherapeuticsPhase 1
26